Skip to content Skip to footer

genome editing

developing first-in-class

advanced therapy

medicinal products (ATMPs)

The mechanism of the Brec1- recombinase

This video is created for Leibniz Institute of Virology (LIV), Hamburg



Oliver Ahnfeld

Co-Founder CEO/CFO

PD Dr. Jan Chemnitz MBA

Co-Founder CEO/CSO

Dr. Niklas Beschorner

Co-Founder Head of RnD

Dr. Maike Voges

Co-Founder Head of QM

Stay up-to-date

Latest News

Working together

Shareholders & Partners

PROVIREX took third place at the 21st Göttingen Innovation Award!
We took third place in the Göttingen Innovation Award 2023 in the category "Companies with up to 20 employees"! Many thanks to WRG Wirtschaftsförderung Region Göttingen GmbH and all sponsors. Newspaper article about it. (only in german) Application video: (only in german)
Official laying of the foundation stone for the new tecHHub building!
In rainy and stormy weather, the official ceremony for the start of the construction of the new tecHHub building for our production rooms in Hamburg was held today with Senator Dr. Melanie Leonhard. The planned completion date is the end of 2023. We are happy…
PROVIREX has been nominated for the Hamburg 2040 Award!
With this award, the Hamburg Chamber of Commerce (Handelskammer) recognises companies, institutions or individuals who are actively shaping the future of Hamburg, demonstrating innovative strength and promoting the location in the sense of the Hamburg 2040 location strategy developed by the Chamber of Commerce. Original press…

Genome Editing Therapies GmbH

Luruper Hauptstraße 1
22547 Hamburg


Copyright © PROVIREX Genome Editing Therapies GmbH 2023